Your browser doesn't support javascript.
loading
Proteinase-activated Receptor 2: Springboard of Tumors.
Vetvicka, David; Suhaj, Petr; Olejar, Tomas; Sivak, Ladislav; Benes, Jiri; Pouckova, Pavla.
Afiliación
  • Vetvicka D; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic; david.vetvicka@lf1.cuni.cz.
  • Suhaj P; Department of Pathology and Molecular Medicine, Third Medical Faculty, Charles University and Thomayer University Hospital, Prague, Czech Republic.
  • Olejar T; Department of Pathology and Molecular Medicine, Third Medical Faculty, Charles University and Thomayer University Hospital, Prague, Czech Republic.
  • Sivak L; Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic.
  • Benes J; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Pouckova P; Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Anticancer Res ; 44(1): 1-12, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38159988
ABSTRACT
Proteinase-activated receptors (PARs) were discovered more than 25 years ago and since then, their role in cancer has been under investigation. Research has primarily focused on the receptors located on the membrane of cancer cells and their impact on metabolism, intracellular signalling, and proliferation. Regarding the host response to cancer, studies have predominantly examined the relationship of thrombin receptors (PAR-1, PAR-3, and PAR-4) with blood clotting in distant metastatic spread. However, limited studies have examined the role of PARs, especially PAR-2, in the host anti-tumor immunity. This review article provides insights into the role of PAR-2 on cancer cells and immune competent cells involved in cancer development and progression. It also discussed the current knowledge of the importance of PAR-2 activation at various stages of cancer progression and its association with cancer-related pain.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptor PAR-2 / Neoplasias Límite: Humans Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptor PAR-2 / Neoplasias Límite: Humans Idioma: En Revista: Anticancer Res Año: 2024 Tipo del documento: Article